VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$0.19-6.94%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · VNRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into li…
Stated in 2 of 2 supplied quarters. Management reported: ““We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.” ““We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into li…”
““We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that…”
We continue to execute against our plan to improve Volition's financial position and further debt and expense reduction remains a top priority as we seek to maximize stockholder value."
Stated in a supplied disclosure. Management reported: “We continue to execute against our plan to improve Volition's financial position and further debt and expense reduction remains a top priority as we seek to maximize stockholder value."” ““We are continuing to execute against our plan to improve Volition's financial position and further debt and expense reduction remains a top priority moving forward as we seek to maximize stockholder value."” Operating income was $-4.156 million in 2026-Q2.
“In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species.
Stated in 2 of 2 supplied quarters. Management reported: ““In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species.” ““We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species.”
““In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species.”
““We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species.”
Focus on executing licensing agreements with diagnostic and liquid biopsy companies to generate upfront milestone payments, royalties, and recurring revenue.
Manage capital structure including debt reduction and equity offerings to improve financial position and reduce dilution.
Over the trailing year it converted 0.91x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
26 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.